Clinical trial
To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV…
NCT00363545 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00363545 |
|---|---|
| Title | To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants) |
| Official title | A Study to Assess the Immunogenicity, Reactogenicity and Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated HRV Vaccine, Given as a Two-dose Primary Vaccination, in Healthy Infants Previously Uninfected With HRV |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | Lyophilized formulation of HRV vaccine, Liquid formulation of HRV vaccine |
| Enrollment | 1,274 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 12, 2007 |
| Completion | Apr 12, 2007 |
| First posted | Aug 15, 2006 |
| Last update posted | Jun 8, 2018 |
| Countries | Panama |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: